NCT05480878View on ClinicalTrials.gov

Role of Nitazoxanide and Escitalopram in Patients With Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

December 2, 2022

Primary Completion Date

March 25, 2023

Study Completion Date

April 1, 2023

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Placebo

Placebo will be administered to the control group for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

DRUG

Nitazoxanide 500Mg Oral Tablet

All subjects will receive Nitazoxanide 500gm twice daily for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

DRUG

Escitalopram 10mg

All subjects will receive Escitalopram 10 mg/day for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

Trial Locations (1)

Unknown

Tanta university, Tanta

All Listed Sponsors
lead

Tanta University

OTHER